Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07BJZ
|
||||
| Former ID |
DNC006001
|
||||
| Drug Name |
Bbs-Arg-(D-Pip)-Gly-S-(GS)11-Gly-Hir
|
||||
| Indication | Discovery agent | Investigative | [527780] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C148H222N42O65S
|
||||
| Canonical SMILES |
CCC(C)C(C(=O)N1CCCC1C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C<br />(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)<br />C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC3=CC<br />=CC=C3)NC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C<br />(CO)NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C(<br />CO)NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C(C<br />O)NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C(CO<br />)NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C4CCCCN4C(=O)C(CCCN=C(N<br />)N)NS(=O)(=O)C5=CC=C(C=C5)C(C)(C)C
|
||||
| InChI |
1S/C148H222N42O65S/c1-8-72(4)121(145(251)190-41-15-20-101(190)143(249)182-80(32-37-118(222)223)135(241)179-79(31-36-117(220)221)136(242)185-86(44-74-21-25-76(203)26-22-74)140(246)184-84(42-71(2)3)138(244)183-83(146(252)253)29-34-102(149)204)187-137(243)81(33-38-119(224)225)180-134(240)78(30-35-116(218)219)181-139(245)85(43-73-16-10-9-11-17-73)186-141(247)87(45-120(226)227)166-103(205)46-153-122(228)88(59-191)167-104(206)47-154-123(229)89(60-192)168-105(207)48-155-124(230)90(61-193)169-106(208)49-156-125(231)91(62-194)170-107(209)50-157-126(232)92(63-195)171-108(210)51-158-127(233)93(64-196)172-109(211)52-159-128(234)94(65-197)173-110(212)53-160-129(235)95(66-198)174-111(213)54-161-130(236)96(67-199)175-112(214)55-162-131(237)97(68-200)176-113(215)56-163-132(238)98(69-201)177-114(216)57-164-133(239)99(70-202)178-115(217)58-165-142(248)100-19-12-13-40-189(100)144(250)82(18-14-39-152-147(150)151)188-256(254,255)77-27-23-75(24-28-77)148(5,6)7/h9-11,16-17,21-28,71-72,78-101,121,188,191-203H,8,12-15,18-20,29-70H2,1-7H3,(H2,149,204)(H,153,228)(H,154,229)(H,155,230)(H,156,231)(H,157,232)(H,158,233)(H,159,234)(H,160,235)(H,161,236)(H,162,237)(H,163,238)(H,164,239)(H,165,248)(H,166,205)(H,167,206)(H,168,207)(H,169,208)(H,170,209)(H,171,210)(H,172,211)(H,173,212)(H,174,213)(H,175,214)(H,176,215)(H,177,216)(H,178,217)(H,179,241)(H,180,240)(H,181,245)(H,182,249)(H,183,244)(H,184,246)(H,185,242)(H,186,247)(H,187,243)(H,218,219)(H,220,221)(H,222,223)(H,224,225)(H,226,227)(H,252,253)(H4,150,151,152)/t72-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100?,101-,121-/m0/s1
|
||||
| InChIKey |
CZTBIQRSYJGOBZ-NBINKJFGSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Coagulation factor IIa | Target Info | Inhibitor | [527780] | |
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Blood coagulation | ||||
| PathWhiz Pathway | Vitamin K Metabolism | ||||
| Coagulation | |||||
| Reactome | Intrinsic Pathway of Fibrin Clot Formation | ||||
| Common Pathway of Fibrin Clot Formation | |||||
| Gamma-carboxylation of protein precursors | |||||
| Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus | |||||
| Removal of aminoterminal propeptides from gamma-carboxylated proteins | |||||
| Cell surface interactions at the vascular wall | |||||
| Peptide ligand-binding receptors | |||||
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | |||||
| G alpha (q) signalling events | |||||
| Thrombin signalling through proteinase activated receptors (PARs) | |||||
| WikiPathways | Complement and Coagulation Cascades | ||||
| Regulation of Actin Cytoskeleton | |||||
| IL1 and megakaryotyces in obesity | |||||
| Regulation of Insulin-like Growth Factor (IGF) Transport and Uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | |||||
| PTM: gamma carboxylation, hypusine formation and arylsulfatase activation | |||||
| Blood Clotting Cascade | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Thrombin signalling through proteinase activated receptors (PARs) | |||||
| Platelet Aggregation (Plug Formation) | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Formation of Fibrin Clot (Clotting Cascade) | |||||
| Cell surface interactions at the vascular wall | |||||
| Folate Metabolism | |||||
| Vitamin B12 Metabolism | |||||
| Selenium Micronutrient Network | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.